TRACON Pharmaceuticals, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2022-11-14: Study NCT05448820; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Unknown.
- 2020-12-09: Study NCT04480502; Company role Lead sponsor; Phase Phase 2; Status Unknown.
- 2019-07-16: Study NCT03835949; Company role Lead sponsor; Phase Phase 1; Status Unknown.
- 2017-11-09: Study NCT03181308; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2022-11-14 | NCT05448820 YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | Lead sponsor | Phase 1, Phase 2 | Unknown | Advanced Sarcoma; Metastatic Sarcoma; Soft Tissue Sarcoma | 15 | 2025-09 |
| 2020-12-09 | NCT04480502 ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma | Lead sponsor | Phase 2 | Unknown | Undifferentiated Pleomorphic Sarcoma; Myxofibrosarcoma | 207 | 2024-10 |
| 2019-07-16 | NCT03835949 Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer | Lead sponsor | Phase 1 | Unknown | Solid Tumor; Metastatic Cancer | 36 | 2022-06 |
| 2017-11-09 | NCT03181308 Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC | Lead sponsor | Phase 1 | Completed Results posted | Carcinoma, Non-Small-Cell Lung | 11 | 2019-07-22 |
| 2017-05-23 | NCT02987829 Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Metastatic Castrate-resistant Prostate Cancer; Adenocarcinoma, Prostate | 72 | 2020-11-09 |
| 2017-02-13 | NCT02979899 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma | Lead sponsor | Phase 3 | Completed Results posted | Advanced Angiosarcoma | 128 | 2019-08-31 |
| 2016-11 | NCT02560779 Trial of TRC105 and Sorafenib in Patients With HCC | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Hepatocellular Carcinoma | 27 | 2019-08 |
| 2016-03 | NCT02664961 Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) | Lead sponsor | Phase 2 | Terminated Results posted | Gestational Trophoblastic Neoplasia; Choriocarcinoma; Placental Site Trophoblastic Tumor; Epithelioid Trophoblastic Tumor | 3 | 2018-11 |
| 2015-11-02 | NCT02429843 A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | Collaborator Lead: University of Alabama at Birmingham | Phase 1 | Completed | Lung Cancer | 16 | 2019-12 |
| 2015-09 | NCT03780010 Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC | Lead sponsor | Phase 1 | Completed Results posted | Non Small Cell Lung Cancer | 15 | 2019-06 |
| 2015-02-01 | NCT02520063 Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer | Collaborator Lead: University of Alabama at Birmingham | Phase 1, Phase 2 | Completed Results posted | Breast Cancer | 15 | 2022-12-01 |
| 2015-01 | NCT02396511 TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma | Lead sponsor | Phase 2 | Completed Results posted | Choriocarcinoma | 2 | 2017-12 |
| 2013-12-10 | NCT01975519 A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Advanced Soft Tissue Sarcoma | 111 | 2019-03-11 |
| 2013-03-08 | NCT01806064 Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Renal Cell Carcinoma | 173 | 2019-06-12 |
| 2012-05 | NCT01564914 A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma | Lead sponsor | Phase 2 | Completed Results posted | Glioblastoma; Glioblastoma Multiforme | 22 | 2015-06 |
| 2011-07 | NCT01381861 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | Lead sponsor | Phase 2 | Completed Results posted | Recurrent Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma | 23 | 2013-12 |
| 2011-06 | NCT01326481 Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Metastatic Breast Cancer | 19 | 2014-12 |
| 2011-04 | NCT01332721 Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated | Lead sponsor | Phase 1 | Completed Results posted | Adult Solid Tumor | 38 | 2013-12 |
| 2008-06 | NCT00692159 Study of TRC102 in Combination With Pemetrexed in Cancer Patients | Lead sponsor | Phase 1 | Completed | Neoplasm | 28 | 2010-09 |
| 2007-12 | NCT00582985 Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer | Lead sponsor | Phase 1 | Completed | Cancer; Neoplasm Metastasis | 51 | 2011-06 |
| 2007-06 | NCT00492830 Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors | Lead sponsor | Phase 1 | Completed | Cancer; Neoplasm Metastasis | 19 | 2009-11 |
| NCT02354612 Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | Lead sponsor | Expanded_access | No longer available | Solid Tumors |